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Abstract The aim of this study was to assess the severity of
depressive symptoms in postmenopausal women, depending
on serum Mg and Zn levels. The study involved 171 post-
menopausal women from Poland, who were not using meno-
pausal hormone therapy (MHT). The intensity of depressive
symptoms was evaluated using a standard research technique,
the Beck Depression Inventory (BDI). The plasmaMg and Zn
concentrations were measured. Depressive symptoms of dif-
ferent severity levels were diagnosed in 36.8 % of the women.
The mean serum Mg level was 1.53±0.28 mg/dL, and Zn
level was 72±14 μg/dL. The women with higher serum Mg
and Zn levels had less depressive symptoms, and this obser-
vation is a precious information which can be used when
planning depressive disorder prevention programmes.
Keywords Depressive disorder . Postmenopause .
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Introduction
Depressive symptoms may be a natural response to stressful
life events. Still, depression, as a disorder which carries nu-
merous consequences, is an increasingly serious problem of
public health in the whole world [1]. Research results indicate
the relationship between the occurrence of depression and the
development of cardiovascular diseases [2] and neoplasms [3]
as well as a higher risk of suicidal death (mortality rate among
people with mood disorders is approximately 15 %) [4].
Depression causes 11 % of disability cases in the world, and
its incidence rate in the general population ranges from 2 to
9 %. It is also a major problem considering drug consumption,
sick leaves and premature deaths [5]. It is predicted that in the
year 2020, depressive disorder will be the second reason for
disability in the world. The incidence of depressive symptoms
in the general population may reach even 30 %. These prob-
lems affect women twice as often as men [6]. Peri- and
postmenopausal women are at particular risk of mood disor-
ders. About 90 % of them suffer from mental disorders,
manifesting as sudden mood changes, coping problems with
everyday stress, low spirits, fatigability, nervousness, irritabil-
ity, poor concentration, worse memory, somatic complaints
with no response to treatment and full-blown depression [7].
The aim of many contemporary studies is to identify risk
factors of mood disorders and to develop prevention strate-
gies. One of the most important prevention-related aspects is
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the influence of nutritional factors. It has been proved that Mg
deficiency may play an important role in the development of
depression and mood disorders [8–10].
Mg is an element present in many food products. Never-
theless, it has been noticed that the consumption of highly
processed foods may result in Mg deficiency, which happens
especially in highly industrialized countries [11]. There are
hypotheses proposed to explain the role of Mg deficiency in
the pathogenesis of depression. It is believed that it is related
to insufficient levels of this element in some enzymes, hor-
mones and neurotransmitters [12].
Possible relationship between serum Zn concentration and
the occurrence of depression was first suggested in the end of
the 1990s [13]. Further analyses demonstrated that people
with acute episodes of depression had significantly lower
blood Zn levels. It was also noticed that concentrations of this
element reached normal levels after successful antidepressant
treatment [14].
Zn is one of the most important trace elements in human
organisms. It is involved in many mechanisms whose impair-
ment, resulting from Zn deficiency, may lead to depressive
disorders. It takes part in neuromodulatory processes in the
brain, and its role in immunological, antioxidant, transcription
and replication functions makes it essential for proper cellular
metabolism [15].
Mg and Zn deficiency in postmenopausal women may
cause or intensify palpitations, trembling hands and feet,
paraesthesia, immune system disorders, dry and rough skin,
hair loss, apathy, melancholia, concentration problems as well
as impairments in the areas of vision, hearing, taste and smell
[16]. It may also result in the reduced bone mineral density,
which carries the risk of osteoporosis [17, 18]. The aim of this
study was to assess the severity of depressive symptoms in




The study involved 171 postmenopausal women from West
Pomeranian Province (Poland). We used the systematic sam-
pling technique (every third woman was chosen from those
who met inclusion criteria). The women were patients of two
specialist outpatient clinics who were invited to take part in
the preventive gynaecological screening programme. The av-
erage age (±SD) was 56 (±6 years). The women were not
using menopausal hormone therapy (MHT) and had had their
final menstrual period at least 1 year prior to the study. These
women had not been diagnosed as having endocrinological,
cancerous or mental diseases and had not received psychiatric
treatment by the time. They were non-smokers, who
undertook moderate physical activity, and had a low to zero
alcohol intake. They did not use elimination diets (this was
one of the exclusion criteria) and did not take any vitamin or
mineral supplements. All of the patients had normal arterial
blood pressure. Those with diabetes, thyroid disorders and
oncological diseases were excluded. Gynaecological exami-
nation and an ultrasound of the reproductive organs were
performed in all women. Blood was collected to determine
Mg and Zn levels.
The patients were informed about the aim of the study and
gave their written consent to take part. The study was con-
ducted with the consent of the Bioethical Commission of the
PomeranianMedical University in Szczecin (permission num-
ber KB-0080/187/09).
Assessments
The severity of depressive symptoms was assessed using a
standard research instrument, the Beck Depression Inventory
(BDI) [19]. A statistical analysis was performed on women
without depressive symptoms (up to 10 points in the Beck
Depression Inventory) and women with minor, moderate or
severe depressive symptoms (over 20 points in the Beck
Depression Inventory).
Women with axis I mental disorders according to the ICD-10
classification were excluded from the analysis by means of the
PRIME-MD questionnaire and a psychiatric examination [20].
SerumMg concentrations between 1.87 and 2.4 mg/dL and
Zn levels between 75 and 130 μg/dL were accepted as labo-
ratory reference normal values [21]. In order to measure Mg
and Zn concentrations, 5 mL of cubital vein blood was col-
lected after 12 h of fasting using metal-free safety vacutainer
blood collecting tubes without anticoagulant. The blood was
drawn in the treatment room between 0800 and 1000 hours
and delivered to the laboratory in accordance with binding
rules and procedures. The blood was spun down at 4,000 rpm
for 10 min, and the serum was harvested. The serum was
stored at −20 °C until the analysis. Serum Mg and Zn con-
centrations were determined by flame atomic absorption spec-
trometry (PU 9100×, Philips, Cambridge, UK). Diluted serum
samples were introduced directly into the flame. The samples
were diluted into 1:80 ratio with lanthanum solution in hydro-
chloric acid. The analytical wavelengths were 285.2 nm for
Mg and 213.9 nm for Zn. Concentration values were read
from the calibration curve. Internal quality control within the
laboratory was performed on two levels, i.e. using two types
of serum, namely, serum with normal Mg and Zn concentra-
tions and serum with Mg and Zn concentrations below nor-
mal. The simple 2-2SD Westgard rule was used for result
acceptance. This rule states that if one control measure ex-
ceeds the mean ± 2 SD, it is necessary to repeat the control
measurement. If its result is within the expected values, then,
we assume that the previous deviation was a random incident,
The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels 31
and the run should be accepted as ‘in control’. However, if the
control measure exceeds the mean ± 2 SD again, a systematic
error is likely, and the results cannot be accepted as reliable (the
run should be rejected). In such circumstances, troubleshooting
was performed and testing was repeated. The control results
were plotted on Levey–Jennings charts. The laboratory tests
were performed in the Department of Biochemistry and Chem-
istry at the Pomeranian Medical University in Szczecin
(Poland) in accordance with the PN-EN ISO 15189 guidelines.
Statistical Analysis
Statistical analyses were performed using Statistica for Win-
dows. Quantitative variables were characterized by median,
minimum and maximum values. The Kruskal–Wallis test for
multiple independent samples was used in the analyses. The
accepted significance level was p ≤0.05.
Results
The majority of the analysed women did not show any de-
pressive symptoms (63.2 %), while the rest had either mild
(19.9 %) or moderate (12.3 %) depressive symptoms. Severe
depression was only diagnosed in eight women, i.e. less than
5 % of the study group. Due to the small size of this group, it
was eliminated from the further analysis.
Serum Mg levels in the whole population of women in-
volved in this study were low when compared to the normal,
and ranged from 0.87 to 2.36 mg/dL, with an average of 1.53
±0.28 mg/dL. Also, Zn levels suggested deficiency of this
element in the blood serum. The range was from 43 to 118 μg/
dL, with an average of 72±14 μg/dL. Only 12.3 % of women
had Mg levels within the normal range, 5.8 % had
hypermagnesaemia and 81.9 % hypomagnesaemia. Zn con-
centrations above 70 mg/dL were found in 42.7 % and below
70 mg/dL in 57.3 % of women. Pearson’s linear correlation
coefficient was used to analyse the correlation between serum
Mg and Zn levels in the women participating in this study
(−0.0388); however, a significant correlation between these
variables was not found (p >0.05).
It was proved that the median of Mg levels was highest in
the women who did not suffer from mood disorders.
Differences in serum Zn levels in the analysed women were
insignificant, and the highest concentration of this bioelement
was found in the patients with mild depressive symptoms
(Table 1).
The analysis of the results performed with the Kruskal–
Wallis test demonstrated a statistically significant difference in
serum Mg levels between at least two of the analysed groups
with different severity levels of depressive symptoms (p <
0.05). There was also a statistically significant difference in
Zn levels between at least two of the analysed groups with
different severity levels of depressive symptoms (p <0.05)
(Table 2).
The analysis of multiple comparisons demonstrated that the
women with mild depression had significantly lower Mg
levels than those without depressive symptoms (p <0.05).
No significant difference was noted in other group pairs
(p >0.05). The women showing symptoms of moderate de-
pression had significantly lower Zn levels than their counter-
parts with mild depressive symptoms (p <0.05). There were
no statistically significant differences in cases of other group
pairs (p >0.05) (Table 3).
Discussion
Demographic changes in the human population have resulted
in the lengthening of the average lifespan. It is estimated that
today’s women spend about 30 % of their lives in the post-
menopausal period [22]. Mood disorders are very common in
this group. The research conducted by Pérez-López et al.
proved that 45 % of the analysed postmenopausal women
suffered from depressive mood [23].
Depressive symptoms affect more women than men [24].
There are numerous theories proposed to explain the reason
for higher incidence of depressive symptoms among women
in the postmenopausal period. One of them indicates to the
role of Zn and Mg deficiency in the pathogenesis of
depression.
Mutations in the mitochondrial DNA can be associated
both with natural ageing of an organism and the deficiency
of Mg, which is an element contributing to the process of
peroxidation, intracellular storage of calcium ions and apo-
ptosis. Mg is essential for the proper activity of DNA
Table 1 Basic descriptive statis-
tics for Mg and Zn levels with
regard to the severity of depres-
sive symptoms
Min minimum, max maximum
Severity of depressive symptoms No. Percent Mg (mg/dL) Zn (μg/dL)
Median Min–max Median Min–max
No depressive symptoms 108 63.2 1.51 0.86–2.36 64.5 42.9–118.2
Mild depressive symptoms 34 19.9 1.42 1.05–1.78 70.5 46.5–112.5
Moderate depressive symptoms 21 12.3 1.43 1.02–2.02 61.8 45.6–098.1
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polymerase I, RNA polymerase and DNA helicase. Its defi-
ciency results in errors during DNA replication, transcription
and translation [25].
Mg deficiency is associated with lifestyle-related dis-
eases, osteoporosis, brittle bones, depression and senile
dementia [26].
The phenomenon of insufficient Mg supply with food is
common in the elderly population. Other frequent causes of
Mg deficiency include low intestinal absorption of this ele-
ment, reduced Mg bone stores and its excessive urinary ex-
cretion. As was reported by McNair et al., renal Mg excretion
increases in postmenopausal women and is only reduced by
the administration of MHT, which restores the levels of this
mineral to premenopausal levels [25]. Chronic Mg deficiency
may be related to numerous disorders, especially frequent
among the elderly, such as hypertension, cerebral stroke,
atherosclerosis, a myocardial infarction, arrhythmia, glucose
intolerance, insulin resistance, type 2 diabetes, abnormal lipid
metabolism, asthma, a higher risk of sudden cardiac death,
chronic fatigue as well as depression and other neuropsychi-
atric diseases [27].
The incidence of depression in the world is continuously
increasing. The role of Mg in the treatment and prevention of
depression has not been thoroughly explained so far. Mg has
an effect on biological and transduction pathways implicated
in the pathophysiology of depression. Derom et al. [28] con-
ducted the recent literature review on the relationship between
depression and Mg levels. Their analysis proves that higher
Mg levels are accompanied by less severe depressive symp-
toms. These results suggest that Mg can be successfully used
in the treatment for depression; however, reports on this issue
are not clear and confirmed enough. There is also a strong
probability that abnormal Mg metabolism is related to the
occurrence of depression. Magnesium taken as a dietary sup-
plement may help to prevent the development of depression. It
may also be used as a supportive therapy [28].
The lowest Mg and Zn levels were found in those women
who demonstrated the most severe climacteric symptoms.
This partially diverges from the results found in the literature,
since numerous reports show that certain menopausal symp-
toms may be related not only to lower levels of steroid
hormones, especially estrogens, but also, though much less
frequently, to the altered Ca to Mg ratio in blood serum [29].
Similar conclusions were drawn by Park et al., who applied a
4-week supplementation with Mg, and thus reduced inci-
dences and severity of hot flushes in more than a half of the
women examined [30].
In the presented study, the authors proved that the women
with mild depressive symptoms had significantly lower Mg
concentrations in blood serum than those without symptoms
of mood disorders.
It was demonstrated that Zn levels in the group of post-
menopausal women were relatively low [31]. There are many
mechanisms which can help to explain the role of Zn defi-
ciency in the pathogenesis of depression. Zn is an essential
trace element for normal cell function and metabolism [32],
and the big amount of which is found in the brain. It has
Table 2 The Kruskal–Wallis test results for the severity of depressive
symptoms depending on Mg and Zn levels
Severity of depressive symptoms No. S H p
Mg
No depressive symptoms 108 9,611 8.725 0.0127
Mild depressive symptoms 34 2,100
Moderate depressive symptoms 21 1,656
Zn
No depressive symptoms 108 8,643 7.769 0.0206
Mild depressive symptoms 34 3,377
Moderate depressive symptoms 21 1,347
S is a rank sum; H is a Kruskal–Wallis test value; p is a level of
significance for test value
Table 3 Multiple comparison test results for the severity of depressive symptoms depending on Mg and Zn levels
Severity of depressive symptoms No depressive symptoms Mild depressive symptoms Moderate depressive symptoms
p value for multiple comparisons; Mg
Independent variable: depression
H (2, N=163)=8,725,439; p=0.0127
No depressive symptoms 0.010008 1.000000
Mild depressive symptoms 0.010008 0.576585
Moderate depressive symptoms 1.000000 0.576585
p value for multiple comparisons; Zn
Independent variable: depression
H (2, N=163)=7,769,043; p=0.0206
No depressive symptoms 0.113166 0.474926
Mild depressive symptoms 0.113166 0.021791
Moderate depressive symptoms 0.474926 0.021791
H is a Kruskal–Wallis test value; p is a level of significance for test value
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neuromodulatory and regulatory effects on many aspects of
cellular metabolism, including replication and transcription
functions [33, 34]. Zn also contributes also to a higher density
of serotonin receptors in the frontal cortex [35]. Zn plays an
important role in healthy ageing since it prevents neoplastic
cell growth and is involved in mitotic cell division as well as
DNA and RNA repair [36].
Epidemiological population studies carried out by
Maserejian et al. [15] revealed that taking too small amounts
of Zn is associated with the occurrence of depressive symp-
toms in women. Such a relationship was not confirmed in
men. It was also noticed that long-lasting symptoms of the
disease were almost five times more common in those female
patients, treated for depression, who had small Zn intake
through the diet than in the women who took big amounts of
this bioelement [15]. Also, other epidemiological studies em-
phasize the relationship between the intensity of depressive
symptoms and serum Zn levels in Europeans at the age of 60–
84 years [37]. Similar association was observed in Iranian
students [38]. The results presented here demonstrated that
women with moderate depressive symptoms had significantly
lower Zn levels than those with mild depressive symptoms.
Conclusion
Those women with higher serum Mg and Zn levels had less
severe depressive symptoms, and this observation is a pre-
cious information which can be used when planning depres-
sive disorder prevention programmes.
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